Compare IPI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | OVID |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.4M | 522.6M |
| IPO Year | 2007 | 2017 |
| Metric | IPI | OVID |
|---|---|---|
| Price | $34.20 | $2.35 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $25.00 | $4.60 |
| AVG Volume (30 Days) | 190.7K | ★ 2.7M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.14 | 3.90 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $298,328,000.00 | $7,252,000.00 |
| Revenue This Year | $5.01 | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | $61.52 | ★ N/A |
| Revenue Growth | 17.13 | ★ 1181.27 |
| 52 Week Low | $22.55 | $0.48 |
| 52 Week High | $50.34 | $3.11 |
| Indicator | IPI | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 42.08 |
| Support Level | $31.83 | $2.23 |
| Resistance Level | $36.08 | $2.38 |
| Average True Range (ATR) | 1.26 | 0.16 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 19.00 | 6.60 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, where the firm's production facilities are located.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.